miR‑423‑5p serves as a diagnostic indicator and inhibits the proliferation and invasion of ovarian cancer

Tang,Xuebiao; Zeng,Xiaogang; Huang,Yu; Chen,Shibing; Lin,Fang; Yang,Ge; Yang,Nian

doi:10.3892/etm.2018.6015

miR‑423‑5p serves as a diagnostic indicator and inhibits the proliferation and invasion of ovarian cancer

Authors:
- Xuebiao Tang
- Xiaogang Zeng
- Yu Huang
- Shibing Chen
- Fang Lin
- Ge Yang
- Nian Yang
View Affiliations

Affiliations: Department of Medical Laboratory, The Second People's Hospital of Neijiang City, Neijiang, Sichuan 641100, P.R. China, Department of Medical Laboratory, The Traditional Chinese Medicine Hospital of Neijiang City, Neijiang, Sichuan 641000, P.R. China, Department of Gynecology and Obstetrics, Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China, Department of Gynecology, The First People's Hospital of Neijiang City, Neijiang, Sichuan 641000, P.R. China, Department of Oncology, The Second People's Hospital of Neijiang City, Neijiang, Sichuan 641100, P.R. China, Department of Transformational Medicine, The Second People's Hospital of Neijiang City, Neijiang, Sichuan 641100, P.R. China
Published online on: April 2, 2018 https://doi.org/10.3892/etm.2018.6015
Pages: 4723-4730
Copyright: © Tang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (miR)‑423‑5p is a potential target for the diagnosis and therapy of heart failure and cancer. The present study aimed to investigate the expression and role of miR‑423‑5p in ovarian cancer. miR‑423‑5p expression in ovarian tissues and plasma collected from ovarian cancer patients and healthy volunteers was analyzed by polymerase chain reaction analysis. In addition, a cell proliferation assay, clonogenic assay and Matrigel‑based assay were performed to evaluate the role of miR‑423‑5p in ovarian cancer cells. The results demonstrated that miR‑423‑5p was downregulated in ovarian cancer tissues and plasma from ovarian cancer patients, compared with healthy individuals. Of note, miR‑423‑5p expression in ovarian tissues and plasma was demonstrated to be inversely correlated with ovarian cancer progression. Transfection with miR‑423‑5p efficiently increased miR‑423‑5p expression in A2780‑s and A2780‑cp cells, which had low miR‑423‑5p expression. Ectopic overexpression of miR‑423‑5p reduced cell proliferation, colony formation and invasion of ovarian cancer cells. In conclusion, the present study indicated that miR‑423‑5p may serve as a diagnostic indicator and functions as a tumor suppressor in ovarian cancer.

View Figures

View References

1	Chang SJ, Bristow RE, Chi DS and Cliby WA: Role of aggressive surgical cytoreduction in advanced ovarian cancer. J Gynecol Oncol. 26:336–342. 2015. View Article : Google Scholar : PubMed/NCBI
2	Kujawa KA and Lisowska KM: Ovarian cancer-from biology to clinic. Postepy Hig Med Dosw (Online). 69:1275–1290. 2015. View Article : Google Scholar : PubMed/NCBI
3	Dinkelspiel HE, Champer M, Hou J, Tergas A, Burke WM, Huang Y, Neugut AI, Ananth CV, Hershman DL and Wright JD: Long-term mortality among women with epithelial ovarian cancer. Gynecol Oncol. 138:421–428. 2015. View Article : Google Scholar : PubMed/NCBI
4	Devi Uma K, Purushotham N and Jayashree N: Management of ovarian cancer in younger women. Rev Recent Clin Trials. 10:263–269. 2015. View Article : Google Scholar : PubMed/NCBI
5	Gasparri ML, Attar R, Palaia I, Perniola G, Marchetti C, Di Donato V, Farooqi AA, Papadia A and Panici PB: Tumor infiltrating lymphocytes in ovarian cancer. Asian Pac J Cancer Prev. 16:3635–3638. 2015. View Article : Google Scholar : PubMed/NCBI
6	Grisham RN, Hyman DM and Iyer G: Targeted therapies for treatment of recurrent ovarian cancer. Clin Adv Hematol Oncol. 12:158–162. 2014.PubMed/NCBI
7	Au KK, Josahkian JA, Francis JA, Squire JA and Koti M: Current state of biomarkers in ovarian cancer prognosis. Future Oncol. 11:3187–3195. 2015. View Article : Google Scholar : PubMed/NCBI
8	Dong X, Men X, Zhang W and Lei P: Advances in tumor markers of ovarian cancer for early diagnosis. Indian J Cancer. 51 Suppl 3:e72–e76. 2014. View Article : Google Scholar : PubMed/NCBI
9	Slezak-Prochazka I, Durmus S, Kroesen BJ and van den Berg A: MicroRNAs, macrocontrol: Regulation of miRNA processing. RNA. 16:1087–1095. 2010. View Article : Google Scholar : PubMed/NCBI
10	Zhu J, Wang S, Zhang W, Qiu J, Shan Y, Yang D and Shen B: Screening key microRNAs for castration-resistant prostate cancer based on miRNA/mRNA functional synergistic network. Oncotarget. 6:43819–43830. 2015. View Article : Google Scholar : PubMed/NCBI
11	Sun X and Zhang J: Dysfunctional miRNA-mediated regulation in chromophobe renal cell carcinoma. PLoS One. 11:e01563242016. View Article : Google Scholar : PubMed/NCBI
12	Sathyapalan T, David R, Gooderham NJ and Atkin SL: Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis. Sci Rep. 5:168902015. View Article : Google Scholar : PubMed/NCBI
13	Chen Y, Min L, Ren C, Xu X, Yang J, Sun X, Wang T, Wang F, Sun C and Zhang X: miRNA-148a serves as a prognostic factor and suppresses migration and invasion through Wnt1 in non-small cell lung cancer. PLoS One. 12:e01717512017. View Article : Google Scholar : PubMed/NCBI
14	Zedan AH: Heterogeneity of miRNA expression in localized prostate cancer with clinicopathological correlations. PLoS One. 12:e01791132017. View Article : Google Scholar : PubMed/NCBI
15	Gautam A, Kumar R, Dimitrov G, Hoke A, Hammamieh R and Jett M: Identification of extracellular miRNA in archived serum samples by next-generation sequencing from RNA extracted using multiple methods. Mol Biol Rep. 43:1165–1178. 2016. View Article : Google Scholar : PubMed/NCBI
16	Nakamura K, Sawada K, Yoshimura A, Kinose Y, Nakatsuka E and Kimura T: Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol cancer. 15:482016. View Article : Google Scholar : PubMed/NCBI
17	Li SP, Su HX, Zhao D and Guan QL: Plasma miRNA-506 as a prognostic biomarker for esophageal squamous cell carcinoma. Med Sci Monitor. 22:2195–2201. 2016. View Article : Google Scholar
18	Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE and Pinto YM: MiR423-5p as a circulating biomarker for heart failure. Circ Res. 106:1035–1039. 2010. View Article : Google Scholar : PubMed/NCBI
19	Luo P, He T, Jiang R and Li G: MicroRNA-423-5p targets O-GlcNAc transferase to induce apoptosis in cardiomyocytes. Mol Med Rep. 12:1163–1168. 2015. View Article : Google Scholar : PubMed/NCBI
20	Li S, Zeng A, Hu Q, Yan W, Liu Y and You Y: miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas. Neuro Oncol. 19:55–65. 2017. View Article : Google Scholar : PubMed/NCBI
21	Stiuso P, Potenza N, Lombardi A, Ferrandino I, Monaco A, Zappavigna S, Vanacore D, Mosca N, Castiello F, Porto S, et al: MicroRNA-423-5p promotes autophagy in cancer cells and is increased in serum from hepatocarcinoma patients treated with sorafenib. Mol Ther Nucleic Acids. 4:e2332015. View Article : Google Scholar : PubMed/NCBI
22	Fang Z, Tang J, Bai Y, Lin H, You H, Jin H, Lin L, You P, Li J, Dai Z, et al: Plasma levels of microRNA-24, microRNA-320a and microRNA-423-5p are potential biomarkers for colorectal carcinoma. J Exp Clin Cancer Res. 34:862015. View Article : Google Scholar : PubMed/NCBI
23	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
24	Dai L, Cui X, Zhang X, Cheng L, Liu Y, Yang Y, Fan P, Wang Q, Lin Y, Zhang J, et al: SARI inhibits angiogenesis and tumour growth of human colon cancer through directly targeting ceruloplasmin. Nat Commun. 7:119962016. View Article : Google Scholar : PubMed/NCBI
25	Falcetta FS, Lawrie TA, Medeiros LR, da Rosa MI, Edelweiss MI, Stein AT, Zelmanowicz A, Moraes AB, Zanini RR and Rosa DD: Laparoscopy vs. laparotomy for FIGO stage I ovarian cancer. Cochrane Database Syst Rev. 10:CD0053442016.PubMed/NCBI
26	Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al: MicroRNA signatures in human ovarian cancer. Cancer Res. 67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
27	Liang H, Jiang Z, Xie G and Lu Y: Serum microRNA-145 as a novel biomarker in human ovarian cancer. Tumour Biol. 36:5305–5313. 2015. View Article : Google Scholar : PubMed/NCBI
28	Ali S, Saleh H, Sethi S, Sarkar FH and Philip PA: MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer. Br J Cancer. 107:1354–1360. 2012. View Article : Google Scholar : PubMed/NCBI
29	Wan Y, Fei X, Wang Z, Jiang D, Chen H, Wang M and Zhou S: miR-423-5p knockdown enhances the sensitivity of glioma stem cells to apigenin through the mitochondrial pathway. Tumour Biol. 39:10104283176955262017. View Article : Google Scholar : PubMed/NCBI
30	Liu J, Wang X, Yang X, Liu Y, Shi Y, Ren J and Guleng B: miRNA423-5p regulates cell proliferation and invasion by targeting trefoil factor 1 in gastric cancer cells. Cancer Lett. 347:98–104. 2014. View Article : Google Scholar : PubMed/NCBI
31	Li S, Zeng A, Hu Q, Yan W, Liu Y and You Y: miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas. Neuro Oncol. 19:55–65. 2017. View Article : Google Scholar : PubMed/NCBI